Literature DB >> 19917319

Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.

Margaret Okomo-Adhiambo1, Ha T Nguyen, Katrina Sleeman, Tiffany G Sheu, Varough M Deyde, Rebecca J Garten, Xiyan Xu, Michael W Shaw, Alexander I Klimov, Larisa V Gubareva.   

Abstract

The neuraminidase inhibitors (NAIs), oseltamivir and zanamivir, are essential for treatment and prevention of influenza A and B infections. Oseltamivir resistance among influenza A (H1N1) viruses rapidly emerged and spread globally during the 2007-2008 and 2008-2009 influenza seasons. Approximately 20% and 90% of viruses tested for NAI susceptibility at CDC during these seasons, respectively, were resistant to oseltamivir (IC(50) approximately 100-3000 time>those of sensitive viruses), based on the chemiluminescent NA inhibition assay. Pyrosequencing analysis confirmed H274Y mutation (H275Y in N1 numbering) in the neuraminidase (NA) gene of oseltamivir-resistant viruses. Full NA sequence analysis of a subset of oseltamivir-resistant and sensitive virus isolates from both seasons (n=725) showed that 53 (7.3%) had mutations at residue D151 (D-->E/G/N), while 9 (1.2%) had mutations at Q136 (Q-->K) and 2 (0.3%) had mutations at both residues. Viruses with very high IC(50) for oseltamivir and peramivir, and elevated IC(50) for zanamivir, had H274Y in addition to mutations at D151 and/or Q136, residues which can potentially confer NAI resistance based on recent N1 NA crystal structure data. Mutations at D151 without H274Y, did not elevate IC(50) for any tested NAI, however, Q136K alone significantly reduced susceptibility to zanamivir (36-fold), peramivir (80-fold) and A-315675 (114-fold) but not oseltamivir. Mutations at D151 and Q136 were present only in MDCK grown viruses but not in matching original clinical specimens (n=33) which were available for testing, suggesting that these variants were the result of cell culture selection or they were present in very low proportions. Our findings provide evidence that propagation of influenza virus outside its natural host may lead to selection of virus variants with mutations in the NA that affect sensitivity to NAIs and thus poses implications for drug resistance monitoring and diagnostics. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917319     DOI: 10.1016/j.antiviral.2009.11.005

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  38 in total

1.  Emerging influenza antiviral resistance threats.

Authors:  Frederick G Hayden; Menno D de Jong
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

2.  Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.

Authors:  Jennifer L McKimm-Breschkin; Janelle Williams; Susan Barrett; Kim Jachno; Mandy McDonald; Peter G Mohr; Takehiko Saito; Masato Tashiro
Journal:  J Antimicrob Chemother       Date:  2013-06-11       Impact factor: 5.790

3.  Neuraminidase-mediated haemagglutination of recent human influenza A(H3N2) viruses is determined by arginine 150 flanking the neuraminidase catalytic site.

Authors:  Ramona Mögling; Mathilde J Richard; Stefan van der Vliet; Ruud van Beek; Eefje J A Schrauwen; Monique I Spronken; Guus F Rimmelzwaan; Ron A M Fouchier
Journal:  J Gen Virol       Date:  2017-06-13       Impact factor: 3.891

4.  Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis.

Authors:  Susu Duan; David A Boltz; Jiang Li; Christine M Oshansky; Henju Marjuki; Subrata Barman; Richard J Webby; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

5.  [Influenza : clinical symptoms, diagnostics and therapy].

Authors:  G G U Rohde
Journal:  Internist (Berl)       Date:  2011-09       Impact factor: 0.743

6.  Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets.

Authors:  Andrés Pizzorno; Yacine Abed; Chantal Rhéaume; Xavier Bouhy; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

7.  Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013.

Authors:  K Sleeman; V P Mishin; Z Guo; R J Garten; A Balish; A M Fry; J Villanueva; J Stevens; L V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

8.  Management of respiratory viral infections in hematopoietic cell transplant recipients.

Authors:  Dimpy P Shah; Shashank S Ghantoji; Victor E Mulanovich; Ella J Ariza-Heredia; Roy F Chemaly
Journal:  Am J Blood Res       Date:  2012-11-25

Review 9.  Deep sequencing: becoming a critical tool in clinical virology.

Authors:  Miguel E Quiñones-Mateu; Santiago Avila; Gustavo Reyes-Teran; Miguel A Martinez
Journal:  J Clin Virol       Date:  2014-06-24       Impact factor: 3.168

10.  Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza.

Authors:  Phillip J Yates; Nalini Mehta; Joseph Horton; Margaret Tisdale
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.